AstraZeneca Enhances Clinical Research Capabilities in China

AstraZenecaAstraZeneca today announced a strategic partnership with Peking University 3rd Hospital to open its first Clinical Pharmacology Unit (CPU) in China. The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients.

Han Qide, academician and vice chairman of the Standing Committee of the National People's Congress; Sang Guowei, President of China Pharmaceutical Association; Chen Zhongqiang, Dean of Peking University 3rd Hospital; and David Brennan, CEO of AstraZeneca, were present at the opening ceremony.

The CPU will focus on Phase I clinical research, including clinical pharmacology and safety evaluations - steps necessary for launching new medicines in China. Under the co-operative agreement, AstraZeneca will provide Peking University 3rd Hospital with personnel training, system audits and consulting services, and will also invest to upgrade facilities necessary for clinical research of medicines for infections, diabetes, and cardiovascular diseases. The unit will accelerate access to new medicines from overseas and benefit Chinese patients in need. In addition, it is set to expand the capabilities of early phase clinical research for local clinical pharmacology organisations, and take China's clinical research capabilities to a new level through further R&D cooperation and academic exchange with the local medical community.

"AstraZeneca is committed to enhancing clinical research capabilities in China. The CPU is established according to AstraZeneca global standards. The collaboration with Peking University 3rd Hospital is a great example of AstraZeneca's patient-oriented global strategy to strengthen our R&D pipeline for Chinese patients," said David Brennan, CEO of AstraZeneca, at a Press conference following the opening ceremony. "The CPU is using a new and innovative operating model for partnership between AstraZeneca and a premier Chinese University hospital that will result in a faster, more efficient and flexible link between phase I studies and our phase II & III clinical research projects."

With China's rapid economic growth and increasing demand for better healthcare, AstraZeneca has enjoyed sustained business growth, posting a 25 per cent sales increase in China in the first half of 2007. AstraZeneca is also stepping up investment in China: it announced investments of $100 million in R&D last year; followed by the establishment of its R&D base, the AstraZeneca Innovation Centre China (ICC) at Shanghai's Zhangjiang Hi-Tech Park. The ICC's initial therapeutic focus will be on cancer, a major cause of death in China. In addition, AstraZeneca's China sourcing centre was founded in Shanghai in January as part of the company's effort to strengthen global sourcing of active pharmaceutical ingredients.

Mr. Brennan added: "China plays an increasingly important role as an emerging market in AstraZeneca's global strategy. We will continue to implement our vision of being 'In China for China,' with long term planning and investment. We fully support China's national focus on innovation by substantially increasing our R&D investment, both in financial terms and in terms of scientific collaboration. We will ramp up development of innovative medicines for Chinese patients."

About AstraZeneca China
AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of, $26.47 billion in 2006 and leading position in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product. AstraZeneca is ranked No.252 in the world's top 500 multinational companies list compiled by Fortune Magazine (the latest ranking published in 2007). The company has its headquarters in London, with 65,000 employees worldwide.

AstraZeneca China has its headquarters in Shanghai, with 25 branch offices in major cities across China’s mainland. It has nearly 3,000 employees working for the sectors of manufacturing, sales, clinical research and new product development. The manufacturing plant located in Wuxi, Jiangsu province, is AstraZeneca's biggest production base in Asia with an investment of US$170 million. In May 2006, AstraZeneca announced investment of US$100 million to establish its R&D base, the AstraZeneca Innovation Centre China (ICC), at Shanghai's Zhangjiang Hi-Tech Park.

For more information please visit: www.astrazeneca.com.cn

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...